english.prescrire.org > Spotlight > Archives : 2023 > Trimebutine: too many cardiac risks

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2023 : 1 | 30 | 60

Trimebutine: too many cardiac risks

 Adverse Effects  In 2021, using data from 444 575 patients, a Korean team observed that the risk of QT interval prolongation linked to hydroxychloroquine was greater in patients who were also exposed to trimebutine.
Full article available for download by subscribers

  • In France, trimebutine has been marketed since the 1970s as a "regulator of gastrointestinal motility". Oral and injectable forms are available. Just one adverse effect was mentioned with the injectable form: "occasional faintness".
     
  • Over the past decades, hundreds of overdoses of varying severity have been reported, most often with oral formulations. The reported disorders were neurological (loss of consciousness, coma, drowsiness and seizures) and cardiac (bradycardia, ventricular tachycardia, hypertension and QT interval prolongation).

©Prescrire 1 January 2023

Source: "Trimebutine: too many cardiac risks" Prescrire International 2023; 32 (244): 21. Subscribers only.

Enjoy full access to Prescrire International, and support independent information
Share
Share on Facebook Share on Twitter


See also:

"Trimebutine: abuse,
addiction and overdose"
(October 2013)
Pdf, subscribers only

Read more:

All the subjects in
Prescrire's Spotlight
Free >